Abstract Patients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as nonalcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes. However, the use of several antidiabetic agents, such as metformin and sulphonylureas, may be a concern in case of hepatic impairment (HI). New glucose-lowering agents targeting the incretin system are increasingly used for the management of type 2 diabetes. Incretin-based therapies comprise oral inhibitors of dipeptidyl peptidase-4 (DPP-4) (gliptins) or injectable glucagon-like peptide-1 (GLP-1) receptor agonists. This narrative review summarises the available data regarding the use of both incretin-based therapies in patients with HI. In contrast to old glucose-lowering agents, they were evaluated in specifically designed acute pharmacokinetic studies in patients with various degrees of HI and their hepatic safety was carefully analysed in large clinical trials. Only mild changes in pharmacokinetic characteristics of DPP-4 inhibitors were observed in patients with different degrees of HI, presumably without major clinical relevance. GLP-1 receptor agonists have a renal excretion rather than liver metabolism. Specific pharmacokinetic data in patients with HI are only available for liraglutide. No significant changes in liver enzymes were reported with DPP-4 inhibitors or GLP-1 receptor agonists, alone or in combination with various other glucose-lowering agents, in clinical trials up to 2 years in length. On the contrary, preliminary data suggested that incretin-based therapies may be beneficial in patients with CLD, more particularly in the presence of non-alcoholic fatty liver disease. Nevertheless, caution should be recommended, especially in patients with advanced cirrhosis, because of a lack of clinical experience with incretin-based therapies in these vulnerable patients.
Introduction
The complex bi-directional relationship linking the liver and diabetes mellitus has recently gained great interest [1, 2] . Type 2 diabetes mellitus (T2DM) favours non-alcoholic fatty liver disease (NAFLD), progressing from steatosis to non-alcoholic steatohepatitis (NASH), and possibly cirrhosis [3] , while alcoholic cirrhosis and chronic hepatitis C virus are frequently associated with glucose metabolism disturbances [4] . Diabetes, which frequently develops as a complication of cirrhosis, is known as 'hepatogenous diabetes' [5] ; it has a complex pathophysiology combining both impaired insulin secretion and insulin resistance [6, 7] . Liver tests are commonly altered in patients with overweight/obesity and in patients with T2DM. While the prevalence of NAFLD ranges from 10 to 24 % in the general population, it may reach 60-95 % and 28-55 % in severely obese and diabetic patients, respectively [8] . In this context, it has been hypothesised that NAFLD may be considered as a new target for T2DM prevention and treatment [9] .
Managing diabetes in patients with chronic liver disease (CLD) can be challenging because many antihyperglycaemic therapies are contraindicated or must be used with caution for safety reasons [10] . A higher risk of lactic acidosis with metformin, of hypoglycaemia with sulphonylureas, or of hepatotoxicity with the first commercialised thiazolidinedione (troglitazone) has been reported [10] . The scarce review papers about the management of diabetic patients with CLD have focused on general management rather than on the specific use of glucose-lowering agents [11, 12] . In this context, the place of new medications, such as incretin-based therapies, has been almost not considered, except in recent reviews [13, 14] .
Incretin-based therapies include either oral agents acting as inhibitors of the dipeptidyl peptidase-4 (DPP-4), also called gliptins, or injectable agents acting as agonists of the glucagon-like peptide-1 (GLP-1) receptors [15] . By inhibiting the inactivation of both endogenous GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), DPP-4 inhibitors stimulate insulin secretion and reduce glucagon secretion, both in a glucose-dependent manner. This dual effect results in a clinically relevant improvement of glucose control without inducing hypoglycaemia or weight gain (in contrast to sulphonylureas) in T2DM patients [16] . GLP-1 receptor agonists exert a more marked reduction in hyperglycaemia together with a significant weight loss. These metabolic effects are the result of enhanced glucosestimulated insulin secretion, inhibition of glucagon release, delayed gastric emptying and increased satiety due to a direct action in the brain. All of these mechanisms may vary according to the type of GLP-1 receptor agonist used, with different effects on fasting and postprandial hyperglycaemia [17, 18] .
The present review aims to provide an updated analysis of the pharmacokinetic characteristics of incretin-based therapies, both DPP-4 inhibitors and GLP-1 receptor agonists, in patients with various degrees of hepatic impairment (HI). In addition, the reported clinical experience in diabetic patients with CLD [19] and liver safety as assessed in controlled clinical trials are also briefly summarised for these two pharmacological classes targeting the incretin system. This information should help the physician to decide how to use incretin-based therapies in patients with CLD and to better position this pharmacological class in the overall management of T2DM in clinical practice.
Literature Search
To identify relevant studies in this narrative review, an extensive literature search of MEDLINE (based on titles and abstracts) was performed from January 2005 to 1 July 2014, with the names of DPP-4 inhibitors or GLP-1 receptor agonists combined with any of the following terms: ''chronic liver disease'', ''hepatic impairment'' or ''cirrhosis''. Each generic name-sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin for the DPP-4 inhibitors; exenatide, liraglutide, lixisenatide for the GLP-1 receptor agonists-was also combined with each of the various terms corresponding to CLD. No language restrictions were imposed. No a priori specific inclusion or exclusion criteria were imposed during the literature search. Reference lists of original studies, narrative reviews and previous systematic reviews were also carefully examined.
Evaluation of Severity of Hepatic Impairment
Pharmacokinetic studies are of particular interest in subjects with impaired hepatic function if hepatic metabolism accounts for a substantial portion of the absorbed drug [20] . Despite most incretin-based therapies being cleared through the kidneys, pharmacokinetic studies with DPP-4 inhibitors and liraglutide were performed in patients with CLD. In clinical pharmacology, the Child-Pugh score is used to quantify the severity of HI in order to guide the use of drugs in patients with CLD, although the limitations of this approach have been acknowledged [20] . HI is generally classified into three levels of severity using the ChildPugh scores: mild HI (class A = scores 5-6), moderate HI (class B = scores 7-9) and severe HI (class C: scores 10-15). Such classification has been used in the various pharmacokinetic studies described below.
Besides HI itself, renal function should also be considered in diabetic patients with CLD. Indeed, hepatorenal syndrome is a distinctive complication of CLD and cirrhosis [21] . Therefore, renal function should be carefully monitored in all patients with cirrhosis and selection of antidiabetic pharmacotherapy should also take into account the possibility of associated renal impairment in such patients [22] . This is of major importance because the dosage of DPP-4 inhibitors (except linagliptin) should be adjusted to the glomerular filtration rate and there are restrictions regarding the use of GLP-1 receptor agonists in the presence of moderate to severe kidney insufficiency [14, 22] .
Dipeptidyl Peptidase-Inhibitors
Several DPP-4 inhibitors are already available, each characterised by different pharmacokinetic properties [23, 24] . The pharmacokinetic characteristics of the five DPP-4 inhibitors already on the market worldwide-sitagliptin, vildagliptin (except in the USA), saxagliptin, linagliptin and alogliptin-were studied in patients with various degrees of HI (Table 1 ).
Sitagliptin

Pharmacokinetics
The influence of moderate HI on the pharmacokinetics of sitagliptin should be minimal. Indeed, sitagliptin is primarily excreted by renal elimination as unchanged drug, with only a small percentage (approximately 16 %) undergoing hepatic metabolism. Cytochrome P450 (CYP) 3A4 is the major CYP isoenzyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8 [25] . In an open-label study, a single 100-mg oral dose of sitagliptin was administered to patients with moderate CLD (Child-Pugh scores ranged from 7 to 9) and healthy subjects used as controls [26] . The mean area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC ? ) and maximum plasma concentration (C max ) for sitagliptin were numerically higher in patients with moderate HI than in healthy matched control subjects (Table 1) . These slight differences were not considered to be clinically meaningful. Furthermore, moderate HI had no statistically significant effect on the time to C max (t max ), apparent terminal elimination halflife (t b ) and renal clearance of sitagliptin. Thus, moderate HI has no clinically meaningful effect on the pharmacokinetics of sitagliptin in this short-term study [26] . However, no study has been performed in patients with more severe HI neither after long-term administration of the drug.
Hepatic Safety
The efficacy of sitagliptin therapy has been shown in patients with T2DM complicated by NAFLD [27] [28] [29] [30] , NASH [31] or CLD caused by hepatitis C virus [32] . However, one report suggested that NAFLD may adversely affect the glycaemic control obtained with sitagliptin [33] .
In a systematic review and meta-analysis of the longerterm safety of DPP-4 inhibitors in patients with T2DM, hepatotoxiticy was not considered to be a concern [34] . No hepatotoxicity of sitagliptin has been shown in a pooled analysis of 25 clinical studies (Table 2) . Nevertheless, a few cases of drug-induced hepatic injury associated with sitagliptin [35] or of elevated hepatic enzymes potentially associated with sitagliptin [36] have been reported. However, the causal relationship remains uncertain because of the complex medical history of many case reports [37] .
Vildagliptin
Pharmacokinetics
Vildagliptin is primarily metabolised via hydrolysis and the inactive metabolites are predominantly excreted by the kidneys [38] . An open-label, parallel-group study compared the pharmacokinetics of vildagliptin in patients with mild, moderate or severe CLD and in healthy control subjects. All subjects received a single 100-mg oral dose of vildagliptin, and plasma concentrations of vildagliptin were measured up to 36 h post-dose [39] . AUC ?, C max and other pharmacokinetic parameters were only minimally and not significantly influenced by the presence of mild, moderate or severe HI ( Table 1) . Because of this absence of changes in exposure to vildagliptin in patients with mild, moderate or severe HI, the conclusion was that no dose adjustment of vildagliptin is necessary in patients with CLD [39] .
Hepatic Safety
There was initial concern about a possible hepatotoxicity of vildagliptin, and therefore liver safety was particularly checked with this compound. No increase of liver enzymes has been shown in a pooled analysis of 38 controlled trials with vildagliptin (Table 2 ). For mild hepatic enzyme elevations with and without elevated bilirubin levels, the odds ratios for vildagliptin 50 mg twice daily were 1.24 (95 % CI 0.80-1.93) and 1.19 (95 % CI 0.29, 4.90), respectively. The exposure-adjusted incidences of markedly elevated hepatic enzymes and of enzyme elevations with bilirubin C2 times the upper limit of normal with vildagliptin were similar to or lower than those in the all comparators group. For all hepatic-related adverse events, the odds ratio for vildagliptin was 0.87 (95 % CI 0.64-1.19) [40] . These data 
CL R (mL/min) 157 (73) 170 (37) 150 (55) 103 (67) Saxagliptin 10 mg [42, 43] 
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Saxagliptin
Pharmacokinetics
In contrast with other DPP-4 inhibitors, saxagliptin is metabolised in vivo to form an active metabolite, 5-hydroxy saxagliptin (twofold less potent than its parent molecule). Both parent drug and metabolite are excreted primarily via the kidneys [24] . Saxagliptin is largely metabolised by CYP3A4 and CYP3A5 isoforms. The pharmacokinetics of saxagliptin and its pharmacologically active metabolite were compared in non-diabetic subjects with mild, moderate or severe CLD and in healthy adult subjects in an open-label, parallel-group, single-dose (saxagliptin 10 mg) study [42, 43] . As compared with controls, the AUC ? values for saxagliptin were 10, 38 and 77 % higher in subjects with mild, moderate or severe HI, respectively ( Table 1 ). The corresponding values were 22, 7 and 33 % lower, respectively, for 5-hydroxy saxagliptin than in healthy subjects. Saxagliptin C max values were 8 % higher, 16 % higher and 6 % lower in patients with mild, moderate and severe HI, respectively, than in controls (corresponding values for 5-hydroxy saxagliptin: -17, -16 and -59 %, respectively) ( Table 1) . Thus, the increase of the exposure of the parent drug saxagliptin appears to be compensated for by a corresponding decrease of the exposure to its active metabolite, 5-hydroxy saxagliptin. Therefore, no dose adjustment of saxagliptin is recommended for diabetic patients with any degree of HI [43] . However, again, caution should be recommended in patients with advanced CLD.
Hepatic Safety
No specific concern about liver safety of saxagliptin has been reported so far [44] . ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of the normal range 24 area under the plasma concentration-time curve from time zero to 24 h, AUC ? area under the plasma concentration-time curve from time zero to infinity, CI confidence interval, CLD chronic liver disease, CL R renal clearance, CL R0-24 h renal clearance from 0 to 24 h after dosing, C max maximum plasma concentration, CV coefficient of variation, GMR geometric mean ratio CLD/healthy subjects function, NA not available, SD standard deviation, t b terminal plasma half-life, t max time to reach maximum plasma concentration high cardiovascular risk, followed for a median of 2.1 years), no signal of liver toxicity could be detected with saxagliptin 5 mg versus placebo, whatever the biological criterion taken into account (Table 3) [45].
Linagliptin
Pharmacokinetics
In contrast to other DPP-4 inhibitors whose main route of elimination is the kidneys [23, 24] , the elimination of linagliptin is primarily non-renal [46] . Linagliptin undergoes enterohepatic cycling with a large majority (85 %) of the absorbed dose eliminated in faeces via biliary excretion [24] . Given the predominantly non-renal route of elimination, it is particularly important to characterise the pharmacokinetics of linagliptin in patients with HI, in order to clarify potential risks and dosing implications. Consequently, in contrast with other DPP-4 inhibitors, linagliptin was also evaluated in a more sophisticated study testing a multiple-dose administration, rather than only a single-dose administration, in patients with mild to moderate CLD. An open-label, parallel-group study enrolled patients with mild, moderate or severe CLD and healthy subjects to investigate whether HI affects linagliptin pharmacokinetics, pharmacodynamics and tolerability [47] . Primary endpoints were linagliptin exposure following linagliptin 5 mg once daily for 7 days in patients with mild and moderate HI versus healthy subjects. However, in those individuals, pharmacokinetic characteristics were also carefully analysed after the first oral administration. In addition, such pharmacokinetic data were also obtained in patients with severe HI who only received a single 5 mg dose of linagliptin. Data obtained after acute administration are summarised in Table 1 . Because of the initial rapid clearance of non-DPP-4 bound drug, the AUC from time zero to 24 h (AUC 24 ) was considered a more sensitive parameter than AUC ? to detect any effect of HI on linagliptin exposure (beyond 24 h the pharmacokinetics of linagliptin mainly reflect the binding to DPP-4 enzyme and slow dissociation of the linagliptin/DPP-4 complex). Results showed no trend to increased exposure with more severe HI. Rather, AUC 24 and C max tended to be lower in patients with mild to moderate HI than in healthy subjects. The inter-individual variability in single-dose pharmacokinetic parameters was highest among patients with severe HI. After a single dose, the mean AUC 24 in patients with severe HI was similar to that in healthy subjects. C max tended to be lower, although quite similar to mean values obtained in patients with mild or moderate HI (Table 1) . Steady-state pharmacokinetic parameters measured after 7-day linagliptin administration were generally comparable between patients with mild and moderate HI and healthy subjects, with only a slight trend to lower linagliptin exposure ( Table 4 ). The relatively lower linagliptin exposure in patients with HI may appear somewhat surprising, and several explanations may be proposed for this observation, as discussed by Graefe-Mody et al. [47] . The most likely reason for the absence of increased exposure to linagliptin despite HI may be related to the pharmacokinetic and pharmacodynamic properties of the drug. Because linagliptin is predominantly eliminated without involvement of hepatic metabolism and because linagliptin has a high DPP-4 enzyme-binding capacity, preserved hepatobiliary excretion of predominantly unchanged linagliptin is sufficient. After 1 week of administration of linagliptin 5 mg once daily, accumulation based on AUC or C max values and renal excretion of unchanged linagliptin (B7 %) was comparable across groups. Median plasma DPP-4 inhibition was similar in healthy subjects (91 %) and patients with mild (90 %) and moderate (89 %) HI at steady-state trough concentrations, and in patients with severe HI 24 h after a single dose (84 %). Thus, mild, moderate or severe HI did not result in any increase in linagliptin exposure 
Hepatic Safety
Reassuring hepatic safety data have also been reported with linagliptin, as shown in a meta-analysis of eight placebocontrolled trials (Table 2 ) [48] . In the only study where a DPP-4 inhibitor (linagliptin 5 mg) was administered once daily for 7 days in patients with mild and moderate HI, the DPP-4 inhibitor was well-tolerated [47] . Only one case report described a probable linagliptin-induced liver toxicity, but, again, caution is required when interpreting this event [49] .
Alogliptin
Pharmacokinetics
Alogliptin is metabolised into two identified minor metabolites: M-I, an N-demethylated active metabolite via CYP2D6, and M-II, an N-acetylated inactive metabolite. CYP3A4 may also be involved in the formation of other unidentified minor metabolites. Exposure to these two metabolites in plasma, relative to unchanged drug, are \1 and \6 %, respectively, so they are not considered clinically relevant. Metabolism represents only a small part of the elimination of alogliptin, which is mainly renally excreted [23, 24] . After a single oral administration of alogliptin 25 mg, no clinical significant differences in AUC and C max exposure to the parent drug and its active metabolite M-I were observed in subjects with moderate HI (Child-Pugh 7-9) compared with healthy subjects (Table 1 ) [50] . The elimination of both alogliptin and M-I was 2.5 h longer in patients with moderate HI than in normal subjects. However, the magnitude of these increases was not considered clinically relevant. Therefore, no dose adjustment is necessary for patients with mild to moderate HI (ChildPugh classes A and B) [50] . However, these data were reported only as an abstract and therefore caution is recommended [51] . Moreover, subjects with more severe HI were not evaluated [50] .
Hepatic Safety
No hepatoxicity has been reported in the development programme of alogliptin [52] . The cardiovascular outcome study EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) recruited 5,380 T2DM patients after an acute coronary syndrome. They were randomly assigned to alogliptin 25 mg once daily (12.5 mg in case of renal impairment) or placebo. After a median follow-up of 18 months, no signal of hepatotoxicity was detected in the alogliptin group (Table 3 ) [53] . An observational Japanese study reported that hypoglycaemic symptoms under therapy with alogliptin may be associated with liver disease and alcohol consumption [54] .
Glucagon-Like Peptide-1 Receptor Agonists
When oral therapy is not sufficient to control blood glucose, injectable agents may be used. Besides insulin therapy, GLP-1 receptor agonists (exenatide, liraglutide, AUC 24 area under the plasma concentration-time curve from time zero to 24 h, AUC t,ss area under the plasma concentration-time curve at steady-state over the dosing interval t, CI confidence interval, CLD chronic liver disease, CL R(0-24 h),ss renal clearance in the time interval 0-24 h at steady state, C max maximum plasma concentration, C max,ss maximum plasma concentration at steady-state, gCV geometric coefficient of variation, gMean geometric mean, GMR geometric mean ratio CLD/healthy subjects function, t b,ss terminal half-life in plasma at steady state, t max,ss time from last dosing to maximum plasma concentration at steady state over the dosing interval t lixisenatide) offer new opportunities for the management of T2DM [55] . A recent review describes the pharmacokinetics and safety aspects of the currently available GLP-1 receptor agonists [56] . However, almost no data are available yet in patients with CLD, except for liraglutide, which was evaluated in a specific pharmacokinetic study [57] .
Exenatide
Pharmacokinetics
No pharmacokinetic studies with exenatide, either its original formulation or its long-acting release preparation (once-weekly formulation), have been performed in patients with CLD. Because exenatide is cleared primarily by the kidneys, HI is not expected to affect blood concentrations of this GLP-1 receptor agonist and effects on glucose control in T2DM patients [58] .
Hepatic Safety
Exenatide has been shown to improve glucose control in patients with T2DM and concomitant NAFLD [59] [60] [61] or NASH [62] . A recently published animal study suggested that sirtuin 1 (SIRT 1 ), a nicotinamide adenine dinucleotide (NAD)?-dependent protein deacetylase that is considered to be a crucial regulator in hepatic lipid homeostasis, mediates the effect of exenatide on ameliorating hepatic steatosis [63] . An interim analysis of data from the openlabel, uncontrolled extension of three double-blind, placebo-controlled trials examined the metabolic effects of 2 years of exenatide treatment in patients with T2DM. Patients with normal baseline alanine aminotransferase (ALT) had no significant ALT change. However, patients with elevated ALT at baseline had a slight but significant reduction of ALT from baseline and 39 % achieved normal ALT by week 104 [64] . This beneficial effect may be explained by the concomitant weight loss and better glucose control with exenatide, two changes that could reduce NAFLD [61] . Nevertheless, it should be pointed out that no studies or data exist regarding the use of exenatide in patients with HI.
Liraglutide
Pharmacokinetics
Liraglutide is metabolised in vitro by DPP-4 and neutral endopeptidase in a manner similar to that of native GLP-1, AUC ? area under the liraglutide plasma concentration-time curve from time zero to infinity, CI confidence interval, CLD chronic liver disease, CL/F total apparent clearance, C max maximum liraglutide plasma concentration, GMR geometric mean ratio CLD/healthy subjects function, NA not available SD standard deviation, t b terminal plasma half-life, t max time to reach maximum liraglutide concentration, V z /F apparent volume of distribution a At a liraglutide concentration of 10,000 pmolÁL -1 (the between-group differences were even greater at a higher liragutide concentration of 100,000 pmolÁL
although at a much slower rate because it is partially resistant to the action of DPP-4. The metabolite profiles suggest that both enzymes are also involved in the in vivo degradation of liraglutide. The lack of intact liraglutide excreted in urine and faeces and the low levels of metabolites in plasma indicate that liraglutide is completely degraded within the body [65] .
A parallel-group, open-label trial compared the pharmacokinetics of a single dose (0.75 mg injected subcutaneously) of liraglutide in four groups of six subjects with normal liver function and mild, moderate and severe HI [57] . Exposure to liraglutide was not increased by HI (Table 5) . On the contrary, mean AUC ? was highest for healthy subjects and lowest for subjects with severe HI. C max also tended to decrease with HI, while t max was similar across groups. Total apparent clearance and apparent volume of distribution tended to increase with the degree of severity of HI; the difference was significant in patients with severe chronic liver failure compared with subjects with normal liver function. According to the authors, because the t b of liraglutide was not affected by HI, the differences in the overall exposure (AUC ? ) of liraglutide might result primarily from differences in absorption of the drug from the subcutaneous depot rather than differences in its subsequent metabolism. The unbound fraction of liraglutide was very low in all groups, but the observed mean fraction unbound in the group of subjects with severe HI was lower than that in the healthy group. Because the vast majority of liraglutide molecules are reversibly bound to plasma albumin, a decrease in albumin concentration as seen in patients with severe CLD may also result in an increased rate of metabolism of liraglutide by various enzymes. However, this pharmacokinetic effect, resulting in lower plasma concentrations, might be compensated for by a possible enhanced pharmacodynamic effect. Indeed, in the setting of reduced circulating albumin concentrations, an increased free fraction of liraglutide is able to interact with GLP-1 receptors. Because of these diverse effects, data are not conclusive to suggest a dose increase of liraglutide in presence of HI. Thus, the results indicate that patients with T2DM and CLD can use standard treatment regimens of liraglutide. There is, however, currently limited clinical experience with liraglutide in patients with HI [57] .
Hepatic Safety
Individual patient data meta-analysis of the LEAD (Liraglutide Effect and Action in Diabetes) program showed that 26-week therapy with liraglutide 1.8 mg (maximum recommended dose) is safe, well-tolerated and improves liver enzymes in patients with T2DM. As already discussed for exenatide, this effect appears to be mediated by the favourable action of liraglutide on weight loss and glycaemic control [66] . Furthermore, a few data support a beneficial impact of liraglutide on liver inflammation markers in NAFLD patients with T2DM [67] , in obese women with polycystic ovary syndrome and NAFLD [68] , and in one T2DM patient with concomitant cryptogenic cirrhosis [69] . In a recent pilot Japanese study, treatment with liraglutide had a good safety profile and significantly improved liver function and histological features in NASH patients with glucose intolerance [70] . A clinical case of suspected liraglutide-induced autoimmune hepatitis has recently been reported [71] . Although caution is required when interpreting the causal relationship of such an event [37] , further post-marketing studies are needed to define the hepatotoxic potential of liraglutide and other GLP-1 receptor agonists.
Lixisenatide
Pharmacokinetics
The elimination of lixisenatide is expected to follow that of endogenous peptides, with renal filtration followed by tubular reabsorption and subsequent metabolic catabolism [72] . The influence of HI on lixisenatide pharmacokinetic characteristics has not been evaluated. However, no dose adjustment is needed in patients with CLD as hepatic dysfunction is not expected to affect the pharmacokinetics of lixisenatide [73] .
Hepatic Safety
No specific analysis has been performed yet with lixisenatide, but no liver safety concerns have been reported with this new GLP-1 receptor agonist [72] .
Discussion
Despite the fact that incretin-based therapies are rather new approaches in the management of T2DM [15] , their pharmacokinetic characteristics in patients with different degrees of HI have been more extensively investigated and are thereby better known than older glucose-lowering agents such as metformin and sulphonylureas [10] . The pharmacokinetic characteristics of all DPP-4 inhibitors have been assessed in patients with CLD. Whereas vildagliptin [39] , saxagliptin [43] and linagliptin [47] have been evaluated after a single oral dose in patients with mild, moderate or severe HI, sitagliptin [26] and alogliptin [50, 51] have only been tested in patients with moderate HI, according to Child-Pugh staging. Regarding GLP-1 receptor agonists, only liraglutide has been evaluated in a specifically designed study in patients with mild, moderate and severe HI [57] . Because these injectable peptides are mainly cleared by DPP-4 enzymes and via the renal rather than hepatic route, it is understandable that no specific studies have been performed with all GLP-1 receptor agonists [20] .
All studies with DPP-4 inhibitors showed only minimal and probably not clinically relevant changes in pharmacokinetic characteristics whatever the degree of severity of HI. In particular, drug exposure, estimated by either AUC or C max , was not significantly modified. Saxagliptin is the only DPP-4 so far that is metabolised in the liver with the production of an active metabolite, 5-hydroxy-saxagliptin, whose capacity of inhibition of the enzyme DPP-4 is almost half of the parent drug [23, 24] . Thus, in the pharmacokinetic study performed in patients with various degrees of CLD, the increase in saxagliptin exposure is probably compensated for by a corresponding decrease in the exposure to its active metabolite, suggesting that no dose adjustment is mandatory for patients with any degree of HI [43] . Nevertheless, caution should probably be recommended, at least in patients with severe HI.
The results of the pharmacokinetic study performed with liraglutide in CLD patients illustrate the complex condition of some patients with severe HI, including late-stage cirrhosis. Indeed, in the group with severe HI, lower exposure to liraglutide, possibly related to reduced subcutaneous absorption or an increased volume of distribution, may at least partially be compensated for by a lower mean unbound fraction of liraglutide in this group than in the healthy group; this latter effect results from decreased albumin concentrations secondary to the severe HI [57] . These data suggest that results may vary from patient to patient in this vulnerable group of individuals with severe CLD. Thus, this complex situation requires much caution when using GLP-1 receptor agonists in this population, particularly because no information is available so far for exenatide and lixisenatide.
Whereas only minimal pharmacokinetic changes have been reported after short-term administration of the five DPP-4 inhibitors currently available worldwide, no single study has evaluated the pharmacokinetics after long-term administration in diabetic patients with CLD. Only linagliptin has been evaluated after a 7-day short-term administration allowing steady-state plasma concentrations [47] . Even if no significant changes were described in steadystate pharmacokinetic characteristics in patients with mild to moderate CLD, it should be pointed out that patients with severe HI were only investigated after a single-dose administration in this study [47] . Thus, caution is required, especially in patients with severe HI. In contrast to patients with CLD, several studies have been published in patients with chronic kidney disease that combine not only pharmacokinetic analysis after a single administration but also clinical efficacy/safety data after long-term administration of up to 1 year in T2DM patients [22] . Such longterm clinical studies are not available in diabetic patients with CLD. Finally, it is also important to check kidney function regularly in individuals with advanced CLD, because the rather high prevalence of the hepatorenal syndrome in this population that may impact on the pharmacokinetic characteristics of the incretin-based therapies [21] .
Anecdotal case reports have raised some concern about a possible hepatotoxicity of DPP-4 inhibitors. However, it is always difficult to confirm a causal relationship in such observational reports because of the presence of many confounding factors [37] . Pooled analyses of large clinical trials with sitagliptin [34] , vildagliptin [40] and linagliptin [48] (Table 2) as well as data from the two recently published major cardiovascular outcome studies reporting liver safety data with saxagliptin [45] and alogliptin [53] ( Table 3 ) are reassuring. On the contrary, some preliminary data suggest that inhibition of DPP-4 might be beneficial in CLD [74, 75] . The serum DPP-4 activity and the staining intensity of DPP-4 in liver are correlated with histopathologic grade NASH and hepatosteatosis. Thus, DPP-4 can be proposed as a novel candidate with several potential functions in NASH pathogenesis [74] . Another recent paper suggested that DPP-4 may be a key player in CLD, a finding that may open new perspectives for the use of DPP-4 inhibitors in patients with CLD [75] . However, no clinical study of long-term administration of a DPP-4 inhibitor in patients with CLD is available yet. Interestingly, the LEAN (Liraglutide Efficacy and Action in NASH) trial is currently investigating whether a 48-week treatment with liraglutide 1.8 mg will result in improvements in liver histology in patients with NASH [76] . Another attractive finding in humans showed that glucoseinduced GLP-1 secretion is deficient in patients with NA-FLD, an observation that paves the way for using incretinbased therapies in these patients [77] . However, these data should be confirmed in patients well-matched for body mass index (BMI) because high BMI (present in these patients with NAFLD) is one of the strongest predictors of deficient GLP-1 secretion [78] . Finally, in another study, improved glucose control correlated with liver fat reduction in obese T2DM patients given the GLP-1 receptor agonists exenatide or liraglutide for 6 months [60] . There is growing evidence that incretin-based therapies have beneficial effects on hepatocytes; however, further study analysis is needed to assess the long-term effect of incretinbased therapies on NAFLD [19] .
It is important to know the pharmacokinetic/pharmacodynamic characteristics of incretin-based therapies in patients with HI because these glucose-lowering agents are increasingly used in clinical practice and because the number of patients with both diabetes and CLD is also increasing, especially due to the rapidly progressing prevalence/incidence of NAFLD, NASH and cirrhosis associated with obesity and T2DM. Clinical trials in diabetic patients with CLD would be of interest, as are those that have been performed and reported in patients with chronic kidney disease. Furthermore, long-term clinical experience in real life would add valuable information, even though clinicians should remain cautious when using these drugs in diabetic patients with advanced CLD.
Conclusion
Old antidiabetic drugs (metformin, sulphonylureas) were poorly investigated in patients with CLD and therefore their use is classically contraindicated in patients with moderate to severe HI. Detailed pharmacokinetic data have been published specifically in patients with various degrees of HI with all five available DPP-4 inhibitors and GLP-1 receptor agonists (only liraglutide so far). Overall, the results provide some reassurance, with only limited pharmacokinetic changes that are likely to be of no clinical relevance. The use of glucose-lowering agents such as incretin-based therapies generally improve NAFLD and NASH, particularly due to better glucose control and possibly some weight loss associated with reduced insulin resistance. However, no long-term studies are available demonstrating both the efficacy and safety of DPP-4 inhibitors or GLP-1 receptor agonists in T2DM patients with mild to severe CLD. Thus, caution is recommended, especially in patients with advanced cirrhosis for whom the problem of effectively and safely controlling blood glucose is more crucial and most often requires insulin therapy.
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